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Safety of Daptomycin in Patients Receiving Hemodialysis
Bruce A. Mueller, Pharm.D., Jason A. Crompton, Pharm.D., Brian J. Donovan, Pharm.D.,
Sara Yankalev, Ph.D., and Kenneth C. Lamp, Pharm.D.
Study Objective. To determine the safety of daptomycin administered using a
variety of doses and dosing frequencies in patients receiving intermittent
hemodialysis who had probable or confirmed gram-positive infections.
Design. Analysis of data from the Cubicin Outcomes Registry and Experience
(CORE), a multicenter, retrospective, observational registry.
Setting. Fifty-four study sites, mostly (46%) large teaching hospitals.
Patients. Three hundred ninety-three adults in the CORE registry who
received intermittent hemodialysis between 2005 and 2008.
Measurements and Main Results. The CORE registry is noninterventional
and collects standard-of-care data on daptomycin treatment from health
care institutions. Of the 393 patients, 370 (94%) could be categorized by
daptomycin dosing frequency: every 48 hours (251 patients [64%]), 3
times/week (87 [22%]), and every 24 hours (32 [8%]); the remaining 23
(6%) had unreported dosing frequencies or received a single dose of
daptomycin. Three hundred eighty-four patients (98%) received part of
their daptomycin therapy as an inpatient and 129 patients (33%) received
part of their daptomycin therapy in an intensive care setting. The primary
infection type was bacteremia (224 patients [57%]), and the most common
pathogen was Staphylococcus aureus (155 patients [39%]). Thirty-eight
adverse events possibly related to daptomycin occurred in 28 patients
(7%); increased blood creatine kinase level (7 patients [1.8%]) was the
most common adverse event. Adverse-event rates were similar across all
dosing regimens.
Conclusion. In these patients undergoing hemodialysis, daptomycin was a
well-tolerated treatment for gram-positive infections across several doses
and dosing frequencies. Further study in prospective trials is warranted.
Key Words: antibiotics, daptomycin, gram-positive infection, hemodialysis,
Staphylococcus aureus, vancomycin.
(Pharmacotherapy 2011;31(7):665–672)
Hemodialysis is a life-sustaining treatment for
persons with end-stage renal disease. However,
the use of hemodialysis is complicated by various
issues, including difficulties with vascular access
and infection. Infection of any type is the second
leading cause of death in patients requiring
hemodialysis, with infection causing death in 12–
22% of patients with end-stage renal disease.1
Septic syndrome, for example, is common and
causes more than 75% of infection-related deaths
in the hemodialysis population. Sepsis-related
mortality is 100–300-fold greater in patients
receiving hemodialysis compared with the
general population.1, 2 Most infections in patients
receiving hemodialysis are caused by gram-
positive bacteria, more specifically Staphylococcus
aureus,3 and the incidence of invasive infection
caused by methicillin-resistant S. aureus (MRSA)
in the dialysis population is 113–2256-fold
greater than that in the general population.4
The treatment of infection in patients receiving
hemodialysis is complicated by several factors.
Since many antibiotics used to treat infections in
the hemodialysis population, including infections
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caused by S. aureus, are eliminated primarily
through the kidneys, their administration can be
challenging in this patient population. In
addition, the potential for toxicity may increase
as the plasma concentrations of the drug increase
due to reduced renal clearance. Vancomycin,
which has been the standard therapy for MRSA
infection, shares these characteristics.5 In
addition, vancomycin efficacy appears to be
lower against MRSA infections, with elevated
vancomycin minimum inhibitory concentration
(MIC) values in the susceptible range.6–8
Although extremely rare, the first United States
reports of vancomycin-resistant S. aureus were in
patients receiving hemodialysis.9, 10 In addition,
renal failure is a common independent risk factor
for mortality in various infection types and
clinical settings.11–13 The factors contributing to
increased mortality may be antibiotic related or
due to patient characteristics that complicate
their response to therapy. In either case, addi-
tional information on antibiotic use in this
population is needed.
Daptomycin (Cubicin; Cubist Pharmaceuticals,
Inc., Lexington, MA) is a cyclic lipopeptide that
causes rapid, concentration-dependent bacterial
cell death against gram-positive organisms.14 The
activity of daptomycin, vancomycin, and linezolid
against S. aureus isolates from bacteremic
patients receiving hemodialysis is similar, with
99.8– 100% susceptibility.15 Daptomycin has
demon-strated similar efficacy to vancomycin
and semi-synthetic penicillins in randomized,
multicenter trials of complicated skin and skin
structure infections and bacteremia and
endocarditis, although patients were limited to
those with normal to moderately reduced renal
function.16, 17 Pharmacokinetic analysis reveals
that daptomycin is more than 90% bound to
plasma proteins and primarily is excreted
unchanged by the kidneys in healthy volunteers.
In studies of patients receiving hemodialysis,
protein binding is similar at 90%, clearance is
approximately one third, and the corresponding
half-life and area under the concentration-time
curve are more than doubled compared with
those parameters in patients who have normal-
to-moderate renal impairment.18–20
In patients treated with hemodialysis, the
recommended dosing regimen of daptomycin is 4
mg/kg every 48 hours for complicated skin and
skin structure infections and 6 mg/kg every 48
hours for S. aureus bacteremia or right-sided
endocarditis.20 When possible, daptomycin
should be administered after hemodialysis on
hemodialysis days.20 This may be difficult when
the currently approved every-48-hour dosing
regimen falls on days opposite the thrice-weekly
hemodialysis schedule commonly used by
patients. Consequently, the daptomycin dosing
regimen that is used in the real-life management
of these patients may fall outside of recommended
labeling, since most patients receive intravenous
antibiotics during or immediately after their
dialysis session.
The objective of this study was to describe the
safety profile of daptomycin administered using a
variety of doses and dosing schedules in the
overall treatment of patients receiving hemodialysis
who had probable or confirmed gram-positive
infections, by analyzing data from a large,
retrospective, multicenter registry.
Methods
Data Source
The Cubicin Outcomes Registry and Experience
(CORE) is a multicenter, retrospective, non-
comparative, observational registry implemented
to collect standard-of-care data on daptomycin
use in different types of gram-positive infections
and patients, including those receiving
hemodialysis.21 From the time period of 2005–
2008, patient data and clinical outcomes were
collected in the United States for the CORE
registry. All sites were required to obtain
appropriate local or central institutional review
board approval, and sites were chosen if they
could provide data on a prespecified number of
patients and represented a variety of treatment
settings, including hospitals and outpatient
centers. Patient records were included in the
registry if the patients were treated with one or
more doses of daptomycin and were not
administered daptomycin as part of a clinical
trial.21 Data were abstracted from patient records
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and verified by the investigators at each site. For
the purpose of this analysis, the safety of patients
receiving intermittent hemodialysis was assessed
overall and based on their final dosing frequency
of daptomycin administration when available:
every 48 hours, 3 times/week, or every 24 hours.
Safety Assessment
All patients who received any dose or dosing
frequency of daptomycin were included in the
safety analysis. Throughout the daptomycin
treatment period and up to 30 days after the last
dose of daptomycin, changes in physical findings,
clinical signs and symptoms, and laboratory
values consistent with serious and nonserious
adverse events were to be documented. Adverse
events were considered serious if they resulted in
any of the following: death, a life-threatening
state, disability or incapacity, hospitalization,
congenital anomaly or birth defect, or an important
medical event.
The following additional information was
collected for all adverse events: day of onset
relative to daptomycin initiation, severity (mild,
moderate, severe), relationship to daptomycin
(not related, possibly related), action taken with
daptomycin (none, stopped permanently, dose
reduced, stopped temporarily), other action
taken (none, concomitant drug, procedure
performed, other), outcome (resolved, resolved
with residual effects, death, ongoing, unknown),
and resolution (day of resolution or day of last
contact relative to daptomycin start). All adverse
events were determined by the investigators by
using International Committee on Harmonisation
E2A definitions of seriousness and severity.22
Statistical Analysis
Continuous variables were reported as mean ±
SD or median and range. Categoric variables
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Table 1. Baseline Demographic and Clinical Characteristics of the Study Patients by Daptomycin Dosing Schedule
Daptomycin Dosing Schedule
Every 48 Hours 3 Times/Week Every 24 Hours All Patientsa
Characteristic (n=251) (n=87) (n=32) (n=393)
Weight, median (range), kg 74 (40–174) 67 (36–167) 73 (45–122) 73 (36–174)
No. (%) of Patients
Sex
Male 116 (46) 33 (38) 17 (53) 176 (45)
Female 135 (54) 54 (62) 15 (47) 217 (55)
Age (yrs)
≤ 50 72 (29) 27 (31) 6 (19) 112 (28)
51–65 90 (36) 34 (39) 17 (53) 149 (38)
≥ 66 89 (35) 26 (30) 9 (28) 132 (34)
Location 2 days before
daptomycin administration
Community 52 (21) 21 (24) 12 (38) 91 (23)
Hospital 176 (70) 57 (66) 18 (56) 267 (68)
Nursing home or extended-care 23 (9) 9 (10) 2 (6) 35 (9)
facility
Daptomycin administration setting
Inpatientb 249 (99) 84 (97) 30 (94) 384 (98)
Outpatientb 59 (24) 40 (46) 9 (28) 109 (28)
Intensive care unit anytime 93 (37) 19 (22) 10 (31) 129 (33)
during daptomycin treatmentb
Underlying diseasesc
Hypertension 144 (57) 59 (68) 15 (47) 233 (59)
Diabetes mellitus 116 (46) 49 (56) 19 (59) 196 (50)
Heart failure 54 (22) 12 (14) 3 (9) 75 (19)
Anemia, all hematologic disease 40 (16) 16 (18) 3 (9) 64 (16)
Peripheral vascular disease 26 (10) 17 (20) 6 (19) 50 (13)
Sepsis 36 (14) 7 (8) 2 (6) 47 (12)
Cancerb 26 (10) 9 (10) 8 (25) 45 (11)
Acute coronary syndrome 28 (11) 8 (9) 3 (9) 40 (10)
aIncludes 23 patients with unreported dosing frequency or who received a single dose of daptomycin.
bp<0.05 for every 48 hrs vs 3 times/wk vs every 24 hrs (2 test).
cEach patient could have had more than one underlying disease; only underlying diseases that were ≥ 10% overall are shown.
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were reported as the number and percentage of
patients with the reported characteristic.
Continuous variables were compared by using
the Student t test, Mann-Whitney U test
(Wilcoxon rank-sum), and one-way analysis of
variance, where appropriate. Categoric
comparisons were performed with the 2 test or
Fisher exact test. Statistical significance was
defined as a p value of 0.05 or less. Statistical
analysis was performed by using JMP statistical
software, version 7, and SAS statistical software,
version 9.1 (SAS Institute, Inc., Cary, NC). This
analysis was not powered to address a particular
safety outcome.
Results
Patient Demographics
Of a total of 4554 patients available in the
registry from 2005–2008, 393 (9%) received
intermittent hemodialysis and were included in
this analysis. These patients were treated at 54
different CORE sites, mostly (46%) large
teaching hospitals. Overall, 251 patients (64%)
received a final daptomycin frequency of every
48 hours. The remainder received treatment
either 3 times/ week (87 patients [22%]) or every
24 hours (32 patients [8%]), or dosing frequency
was not reported or patients received only a
single dose of daptomycin (23 patients [6%]).
Initial and final daptomycin dosing frequencies
were unchanged in 365 patients (93%).
Demographic data for all patients and stratified
by daptomycin final dosing schedule are detailed
in Table 1.
In the hemodialysis population overall, more
than half of the patients were female, older than
51 years, and in the hospital 2 days before
daptomycin administration (Table 1). Almost all
patients received daptomycin as an inpatient, and
33% of all patients received some part of their
daptomycin treatment in an intensive care unit
setting. Hypertension and diabetes mellitus were
the most common underlying diseases. No
significant differences were seen in the demo-
graphics among groups by daptomycin dosing
frequency except that the every-48-hours group
had the highest rate of daptomycin treatment in
an intensive care unit and the every-24-hours
group had the highest predominance of cancer.
Infection Types and Pathogens
Most patients were treated for bacteremia; skin
and skin structure infection was the next most
common type of infection. No significant
differences were noted among daptomycin
dosing frequency groups when categorized by
primary infection types except for catheter-
related bacteremia and skin and skin structure
infections (Table 2). The primary causative
pathogen was S. aureus (155 patients [39%]),
with 117 patients (30%) having MRSA.
Although the methodology varied by institution,
the daptomycin MICs for S. aureus, reported for
20 patients, ranged from 0.09–1 mg/L. The
vancomycin MICs for S. aureus, reported for 105
patients, ranged from less than or equal to 0.2
mg/L to 3 mg/L (19 patients [18%] had MICs > 1
mg/L). Enterococci were cultured in 143 patients
(36%); vancomycin-resistant enterococci were
present in 108 patients (27%), most of which
were Enterococcus faecium (77 patients [20%]).
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Table 2. Types of Primary Infection in the Study Patients According to Daptomycin Dosing Schedule
No. (%) of Patients
Daptomycin Dosing Schedule
Every 48 Hours 3 Times/Week Every 24 Hours All Patientsa
Infection Type (n=251) (n=87) (n=32) (n=393) p Value
Bacteremia
Catheter-related 99 (39) 39 (45) 5 (16) 154 (39) 0.01
Non–catheter-related 48 (19) 12 (14) 7 (22) 70 (18) 0.46
Skin and skin structure 40 (16) 14 (16) 12 (38) 70 (18) 0.01
Endocarditis 17 (7) 9 (10) 3 (9) 29 (7) 0.53
Bone and joint 18 (7) 6 (7) 2 (6) 27 (7) 0.98
Urinary tract or pyelonephritis 17 (7) 5 (6) 2 (6) 26 (7) 0.94
Otherb 12 (5) 2 (2) 1 (3) 17 (4) 0.58
aIncludes 23 patients with unreported dosing frequency or who received a single dose of daptomycin.
bOther includes the following: 9 not specified infections, 3 necrotizing infections, 1 not specified foreign device infection, 1 central nervous
system infection, and 1 nonsurgical antibiotic prophylaxis.
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The daptomycin MICs for Enterococcus species,
reported in 22 patients, ranged from 0.19–4
mg/L.
Previous and Concomitant Antibiotic Therapy
Three hundred nine patients (79%) had been
treated previously with an average of 1.3
antibiotics. In these patients, vancomycin was
used most frequently (213 patients [69%]),
followed by -lactams (77 [25%]), linezolid (61
[20%]), aminoglycosides (40 [13%]), fluoro-
quinolones (41 [13%]), and carbapenems (18
[6%]); other antibiotics were used in 41 patients
(13%). There were no significant differences in
use of previous antibiotics among daptomycin
dosing frequency groups. The most common
reason for discontinuation of a previous anti-
biotic was failure (112 patients [36%]). Failure
was documented as a contributing reason to
discontinuation in 72 (34%) of the 213 patients
receiving previous vancomycin. The most
common reasons for discontinuing -lactams
were failure (20/77 patients [26%]) and resistant
pathogens (19/77 [25%]). Linezolid discontinu-
ation reasons were primarily failure (19/61
[31%]) and toxicity or intolerance (16/61 [26%]).
Two hundred forty-one patients (61%)
received daptomycin in combination with an
average of 1.7 different antibiotics. Concomitant
antibiotic use was not significantly different
among dapto-mycin dosing frequency groups. A
-lactam was used most frequently (94 patients
[39%]), followed by an aminoglycoside (53
[22%]), vancomycin (50 [21%]), carbapenem (44
[18%]), fluoroquinolone (43 [18%]), rifampin
(31 [13%]), and linezolid (12 [5%]); other
antibiotics were used in 65 (27%) of the patients
taking concomitant antibiotics.
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Table 3. Adverse-Event Rates in the Study Patients by Daptomycin Dosing Schedule
No. (%) of Patients
Daptomycin Dosing Schedule
Every 48 Hours 3 Times/Week Every 24 Hours All Patientsa
Characteristic (n=251) (n=87) (n=32) (n=393) p Valueb
Any adverse event 63 (25) 14 (16) 10 (31) 94 (24) 0.13
Any possibly related adverse event 17 (7) 7 (8) 2 (6) 28 (7) 0.91
Any serious adverse event 38 (15) 9 (10) 4 (13) 55 (14) 0.52
Any serious and possibly related adverse 3 (1) 2 (2) 0 (0) 6 (2) 0.59
event
Discontinuation due to adverse event 12 (5) 3 (3) 2 (6) 20 (5) 0.79
Deaths 31 (12) 5 (6) 3 (9) 42 (11) 0.22
Most common adverse events by
MedDRA preferred term (> 1% overall)c
Hypotension 7 (2.8) 2 (2.3) 1 (3.1) 10 (2.5)
Increased blood CK level 4 (1.6) 2 (2.3) 2 (6.3) 8 (2.0)
Cardiorespiratory arrest 5 (2.0) 1 (1.1) 0 (0) 7 (1.8)
Diarrhea 7 (2.8) 0 (0) 0 (0) 7 (1.8)
Rash 4 (1.6) 0 (0) 0 (0) 5 (1.3)
Respiratory failure 5 (2.0) 0 (0) 0 (0) 5 (1.3)
Sepsis 3 (1.2) 0 (0) 1 (3.1) 5 (1.3)
Cardiac arrest 3 (1.2) 0 (0) 1 (3.1) 4 (1.0)
Septic shock 3 (1.2) 0 (0) 0 (0) 4 (1.0)
Thrombocytopenia 3 (1.2) 1 (1.1) 0 (0) 4 (1.0)
Most common possibly related
adverse events (> 0.5% overall)c
Increased blood CK level 3 (1.2) 2 (2.3) 2 (6.3) 7 (1.8)
Rash 3 (1.2) 0 (0) 0 (0) 4 (1.0)
Eosinophilia 2 (0.8) 1 (1.1) 0 (0) 3 (0.8)
Diarrhea 2 (0.8) 0 (0) 0 (0) 2 (0.5)
Hyponatremia 1 (0.4) 1 (1.1) 0 (0) 2 (0.5)
Pyrexia 1 (0.4) 1 (1.1) 0 (0) 2 (0.5)
Thrombocytopenia 2 (0.8) 0 (0) 0 (0) 2 (0.5)
MedDRA = Medical Dictionary for Regulatory Activities; CK = creatine kinase.
aIncludes 23 patients with unreported dosing frequency or who received a single dose of daptomycin.
bCalculated only for patients with known dosing frequency (every 48 hrs vs 3 times/wk vs every 24 hrs).
cEach patient could have had more than one adverse event.
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Dose and Frequency of Daptomycin
The median final daptomycin dose was 6
mg/kg (range 2–14.75 mg/kg); patients with skin
and skin structure infection and/or urinary tract
infections or pyelonephritis received a median of
4 mg/kg (range 2–10 mg/kg), and those with all
other infection types received a median of 6
mg/kg (range 2–14.75 mg/kg). The median dose
in patients receiving treatment every 24 hours
was 4 mg//kg (range 2–7 mg/kg) compared with
6 mg/kg (range 3–14.75 mg/kg) in the every-48-
hours group, and 6 mg/kg (range 3–9.5 mg/kg)
in the 3 times/week group. By infection type, the
every-24-hours group had the lowest median
dose for all categories except for skin and skin
structure infections and the group of other
infections. Data were not collected to determine
if the daptomycin dose was based on ideal or
total body weight.
The median duration of therapy was 12 days
(range 1–84 days). The median daptomycin
duration of therapy was longest for bone and
joint infections (17.5 days) and endocarditis (15
days) and was shortest for skin and skin
structure infections and urinary tract infections
or pyelonephritis (10 days) and the group of
other infections (6 days). The median duration
was shortest in the every-24-hours group (10.5
days) compared with the every-48-hours group
(12 days) and 3 times/week group (15 days,
p=0.01). For patients who received previous
and/or follow-up antibiotics, the daptomycin
duration represents a portion of the total
duration of therapy.
Safety
A total of 200 adverse events occurred in 94
patients (24%) overall, with 38 adverse events in
28 patients (7%) classified as possibly related to
daptomycin. The occurrence of adverse events
including those possibly related to daptomycin
was not affected significantly by dosing
frequency (Table 3). Of those possibly related to
daptomycin, increased blood creatine kinase level
was the most common, occurring in 7 patients
(1.8%); the frequency of increased creatine
kinase level was not significantly different among
the dosing frequency groups. Rash and
eosinophilia were reported in 4 (1%) and 3
(0.8%) patients, respectively. Diarrhea,
hyponatremia, pyrexia, and thrombocytopenia
occurred in 2 patients (0.5%) each. Nine adverse
events (bacterial sepsis, eosinophilia, urticaria,
renal insufficiency, pancytopenia, catheter site
discharge, Klebsiella infection, Pseudomonas
infection, and rhabdomyolysis) in 6 patients
(2%) were reported as serious and possibly
related to daptomycin. Twenty patients (5%)
discontinued daptomycin because of an adverse
event; 12 (3%) had an adverse event that was
possibly related to daptomycin. In addition, no
significant difference in number of patients
experiencing any adverse event was observed
when stratified by daptomycin dose (44/166
[27%] for < 6 mg/kg vs 48/217 [22%] for ≥ 6
mg/kg, p=0.3). The overall mortality rate was
11% (42/393): 12% (31/251) for the every-48-
hour group, 6% (5/87) for the 3 times/week
group, 9% (3/32) for the every-24-hour group,
and 13% (3/23) in the remaining patients.
Discussion
In patients treated with hemodialysis, the
administration of many drugs is challenging,
especially those drugs that are eliminated
through the kidneys. For antibiotics, this is
especially problematic since appropriate dosing is
necessary in order to eradicate the pathogen(s),
prevent development of resistance, and avoid
toxicity.
Since its introduction, daptomycin has been
used frequently across a variety of infection types
with good clinical outcomes.23 The data from
this analysis of the CORE registry from
2005–2008 showed that the rate of adverse
events from daptomycin was similar across
dosing frequency groups.
There has been a need for additional safety
data with daptomycin in this population as
slower elimination and higher troughs might lead
to higher adverse-event rates. However, rates of
adverse events generally were similar to those
found in randomized, multicenter trials of
daptomycin.16, 17 With respect to adverse events
judged to be possibly related to daptomycin, only
2% were classified as serious. An elevated
creatine kinase level was observed in less than
2% of patients in the population evaluated in the
safety analysis. It is noteworthy that daptomycin
yielded similar results across all dosing frequency
groups without the need for therapeutic drug
monitoring, which is often recommended for
vancomycin and teicoplanin. The every-24-hour
dosing interval is not recommended in patients
receiving hemodialysis since the prolonged half-
life will lead to higher trough concentrations
than those seen in patients with normal renal
function. Data accumulated to date suggest that
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daptomycin-associated muscle toxicity is related
to an inadequate amount of time between doses
where the minimum serum concentration may be
elevated.24 The daptomycin dose was not
significantly different between those who
developed an elevated creatine kinase level and
those who did not. It is unknown if the lower
dose used in patients receiving daptomycin every
24 hours may have mitigated the occurrence of
adverse events. Further data are expected from
an ongoing prospective study of patients with
moderate or severe renal dysfunction comparing
daptomycin with vancomycin for patients with
skin and skin structure infections or S. aureus
bacteremia.25
The overall mortality rate of 11% in this
analysis is similar to published data in this
population. One group of authors investigated
the outcomes of first-time infections in
hospitalized patients receiving hemodialysis.26
An outcome of death occurred in 13.8% of first-
time infections. The types of infections were
similar in frequency to those described in this
analysis, with a preponderance of bacteremia and
access-related infections and lower rates of
cardiac, skin, and urinary tract infections. One
notable difference was the absence of pulmonary
infections in the CORE registry due to
daptomycin’s lack of efficacy in this setting.20
Limitations
The retrospective nature of the registry has
several important limitations that prevent
drawing firm conclusions regarding the safety of
daptomycin in the treatment of gram-positive
infections in the hemodialysis population. There
was no control group; all patients in the registry
had received daptomycin in addition to other
treatment options including concomitant anti-
biotics and surgical interventions as appropriate.
Many variables were not controlled, as patients
were managed at the discretion of their physi-
cians, which, while a limitation, also provides
real-world perspective. Thus, safety outcomes
and mortality may have been influenced by
factors other than the use of daptomycin.
The patient population was diverse, with a
variety of infections and pathogens. Although
reflective of real-world clinical practice, the
number of subjects in any particular subgroup
was small. Susceptibility data were incomplete,
making it difficult to identify any association
between in vitro activity of daptomycin and
mortality. There was no patient follow-up after
the completion of daptomycin therapy; thus,
identifying late adverse events was not possible.
Finally, details on the administration of hemo-
dialysis, information on different variables such
as duration, type of filter, and flow rates were not
collected as part of the CORE registry during this
time period. These and other factors may alter
significantly the amount of drug clearance during
a dialysis session.27 This information was cap-
tured in 2009, and 66% of patients undergoing
intermittent dialysis received their daptomycin
after dialysis. Although the product labeling of
daptomycin recommends administration after
hemodialysis sessions,20 strict assurance that
study patients received it in such a manner was
not captured.
Conclusion
The safety data in this analysis of daptomycin
in patients receiving hemodialysis who had a
variety of gram-positive infections suggest that
daptomycin as part of the standard of care in this
setting may be a well-tolerated treatment option.
The adverse events reported during daptomycin
treatment appeared similar across all doses and
dosing frequencies that are commonly used to
treat infections in patients receiving hemodialysis,
including 3 times/week. Further study in prospec-
tive clinical trials is warranted.
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